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Objective: To investigate the potential differential effects of selective endothelin (ET) A and dual ET-A/B
receptor blockade in patients with chronic heart failure.
Methods: Nine patients with chronic heart failure (New York Heart Association class II–III) each received
intravenous infusions of BQ-123 alone (selective ET-A blockade) and combined BQ-123 and BQ-788
(dual ET-A/B blockade) in a randomised, placebo controlled, three way crossover study.
Results: Selective ET-A blockade increased cardiac output (maximum mean (SEM) 33 (12)%, p , 0.001)
and reduced mean arterial pressure (maximum 213 (4)%, p , 0.001) and systemic vascular resistance
(maximum 226 (8)%, p , 0.001), without changing heart rate (p = 0.38). Dual ET-A/B blockade
significantly reduced the changes in all these haemodynamic variables compared with selective ET-A
blockade (p , 0.05). Selective ET-A blockade reduced pulmonary artery pressure (maximum 25 (7)%,
p = 0.01) and pulmonary vascular resistance (maximum 72 (39)%, p , 0.001). However, there was no
difference between these effects and those seen with dual ET-A/B blockade. Unlike selective ET-A
blockade, dual ET-A/B blockade increased plasma ET-1 concentrations (by 47 (4)% with low dose and 61
(8)% with high dose, both p , 0.05).
Conclusions: While there appeared to be similar reductions in pulmonary pressures with selective ET-A
and dual ET-A/B blockade, selective ET-A blockade caused greater systemic vasodilatation and did not
affect ET-1 clearance. In conclusion, there are significant haemodynamic differences between selective ET-A
and dual ET-A/B blockade, which may determine responses in individual patients.
E
ndothelin (ET) 1 is a potent endogenous vasoconstrictor
in humans and contributes to the maintenance of basal
vascular tone1 and blood pressure2 in healthy people and
patients with systemic arterial hypertension.3 4 It acts
through two receptor subtypes: the ET-A and ET-B receptors.
While both receptors are expressed on vascular smooth
muscle cells and mediate vasoconstriction, only the ET-B
receptor is located on the endothelium, where it produces a
prostanoid and nitric oxide mediated vasodilatation. Thus,
ET-B receptor mediated effects are complex and include
vasoconstriction, endothelium dependent vasodilatation, and
a role in the clearance of ET-1.5 In healthy people, in contrast
to the vasodilator and vasodepressor effects of ET-A receptor
blockade,6 7 systemic ET-B receptor blockade has vasocon-
strictor and pressor effects,8 suggesting that the vascular
balance of basal ET-B receptor activation favours vasodilata-
tion.
Chronic heart failure is associated with neurohumoral
activation as a consequence of reductions in cardiac reserve,
systemic blood pressure, and renal perfusion. This leads to
peripheral vasoconstriction, increased systemic vascular
resistance, and sodium and water retention, which together
increase cardiac work and further compromise cardiac
performance. Many regulatory mechanisms are involved in
this maladaptive response, including the renin–angiotensin,
sympathetic nervous, and vasopressin systems. The ET
system also appears to contribute to the pathophysiology of
heart failure, which is associated with increased plasma ET-1
concentrations9 10 that correlate with haemodynamic
changes,11 12 reduced exercise capacity,13 and a poor prog-
nosis.14
In patients with chronic heart failure, systemic adminis-
tration of both selective ET-A15–17 and non-selective ET-A/B
blockade18–21 reduces systemic vascular resistance and
increases cardiac output. In patients with acute decompen-
sated heart failure systemic administration of non-selective
ET-A/B blockade has been shown to have beneficial effects.22
However, systemic ET-B blockade increases systemic vascular
resistance and has potentially detrimental effects in patients
with chronic heart failure.23 Therefore, the question arises as
to whether differences between selective ET-A and non-
selective ET-A/B blockade can influence haemodynamic
responses to ET blockade, which in turn might have
contributed to the recent failure of ET blockade as a
treatment approach for patients with chronic heart fail-
ure.24 25 However, to date, there have been no direct studies
comparing these two approaches.
The objectives of this placebo controlled study, in patients
with stable chronic heart failure, were to compare in a head
to head manner the effects of selective ET-A blockade with
non-selective ET-A/B blockade on systemic and pulmonary
haemodynamic function.
METHODS
Patient selection
Nine patients with chronic heart failure (New York Heart
Association (NYHA) class II–III) caused by left ventricular
dysfunction were recruited if they had an ejection fraction
( 35% (by echocardiography with the biplanar Simpson’s
rule) and had been stable with treatment, including
angiotensin converting enzyme inhibitor or angiotensin
receptor antagonist, for at least three months. Patients were
all in sinus rhythm and no patient had a pacemaker or
implantable cardiac defibrillator. Patients were excluded if
they had insulin dependent diabetes mellitus, abnormal liver
function, renal impairment (creatinine . 200 mmol/l for
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men; . 180 mmol/l for women) or a systolic blood pressure
. 190 or , 90 mm Hg, or within three months had under-
gone coronary artery bypass graft surgery or percutaneous
coronary intervention or had an acute coronary syndrome,
myocardial infarction, or cerebrovascular accident.
The study was undertaken with the approval of the local
research ethics committee and in accordance with the
Declaration of Helsinki. Written informed consent was
obtained from each patient before entry into the study.
Measurements
Blood pressure and heart rate were measured non-invasively
with a Dynamap compact TS (Critikon LLC, Ascot, UK).
Cardiac output, mean pulmonary artery pressure, pulmonary
artery wedge pressure, and central venous pressure were
measured continuously with a single multilumen thermo-
dilution cardiac output pulmonary artery catheter (Swan-
Ganz CCOmbo—CCO/SVO2; Edwards Lifesciences, Irvine,
California, USA). Cardiac output was calculated automati-
cally (Vigilence, Edwards Critical Care, Baxter’s Healthcare
Corporation, Irvine, California, USA) and, at each time point,
the cardiac output was taken as the mean of three
measurements.
Protocol
All patients attended fasted at 7.30 am on three occasions at
least one week apart. Patients were asked to omit their
regular medications on the morning of the study. The studies
were conducted in a quiet, draught-free room maintained at
a constant temperature (22–24 C˚). A pulmonary artery
catheter was inserted through a 9 French femoral venous
sheath into the right pulmonary artery and was flushed with
0.9% heparinised saline. Before starting drug administration,
patients underwent an equilibration period of . 90 minutes
until blood pressure, heart rate, and cardiac output were
stable, with three consecutive measurements within 10%.
Study drugs were administered by 15 minute infusion in two
incremental doses 60 minutes apart.
Drug administration
A venous cannula for drug administration was inserted under
local anaesthesia. Pharmaceutical grade BQ-123 and BQ-788
(Clinalfa AG, La¨ufelfingen, Switzerland) were dissolved in
0.9% saline (Baxter Healthcare Ltd, Thetford, UK). On each
study day, patients received a low dose infusion at t = 0 for
15 minutes followed by a high dose infusion at t = 60
minutes for 15 minutes. On different study days and in
random order, patients received saline placebo, BQ-123 (low
dose, 1.5 mmol; high dose, 15 mmol) alone or the co-infusion
of BQ-123 (low dose, 1.5 mmol; high dose, 15 mmol) and BQ-
788 (low dose, 0.45 mmol; high dose, 4.5 mmol). These doses
were selected following studies in healthy volunteers given
BQ-123 and BQ-788. This dose of BQ-123 was sufficient to
reduce systemic vascular resistance and block the effects of
local infusion of ET-1 into the forearm.7 This dose of BQ-788
was sufficient to reduce systemic vascular resistance.8 The
detailed rationale for these doses has been discussed
elsewhere.26
Blood sampling and plasma assays
Venous blood for ET-1 and big ET-1 (the 38 amino acid
precursor of ET-1) assay was taken from the femoral vein.
Blood was collected into 0.16% EDTA (Sarstedt, Aktiengesell-
schaft & Co, Numbrecht, Germany) and immediately
separated by centrifugation (2500 g for 20 minutes at 4 C˚)
and stored at 280 C˚ until analysis. Following extraction in
Bond Elut columns (Varian, Harbor City, California, USA),
ET-1 (Peninsula Laboratories Europe Ltd, St Helens, UK) and
big ET-1 (Peninsula Laboratories Europe Ltd) concentrations
were determined by radioimmunoassay as previously
described.27 The intra-assay coefficients of variability were
7.0 and 7.2%, respectively, and the interassay coefficients of
variability were 9.0 and 9.3%, respectively.
Table 1 Patient characteristics and medications
Patient
Age
(years)
BMI
(kg/m2)
BP
(mm Hg)
HR
(beats/min)
MPAP
(mm Hg)
PAWP
(mm Hg) Cause of HF NYHA Drugs and dose*
1 75 26 186/79 52 20 11 Ischaemic III ASA75, En20, Bu1, Sim20
2 63 23 120/74 64 13 6 Idiopathic II ASA75, En20
3 60 27 122/58 62 17 12 Ischaemic III Val80, Frus40
4 43 30 98/64 77 12 8 Ischaemic II ASA75, Lis10, Frus40
5 56 29 139/88 96 11 6 Ischaemic III ASA75, Lis20, Frus40, Car12.5,
Dig250, Sim20
6 61 26 136/77 66 16 12 Ischaemic III ASA75, Lis10, Frus40, Spir25,
Dig125, Sim20
7 52 36 184/106 94 25 23 Ischaemic III Lis15, Frus20, Aten100
8 74 33 143/75 58 14 10 Ischaemic III ASA75, Lis10, Frus40, Bis10,
Sim10
9 67 21 154/78 65 14 10 Ischaemic II ASA75, Lis10, Aten50, Pra20
Average 61 28 142/78 70 16 11
SEM 3 1 9/4 5 1 2
*Doses in mg except for digoxin (mg).
ASA, aspirin; Aten, atenolol; Bis, bisoprolol; BMI, body mass index; BP, blood pressure; Bu, bumetanide; Car, carvedilol; Dig, digoxin; En, enalapril; Frus,
furosemide; HF, heart failure; HR, heart rate; Lis, lisinopril; MPAP, mean pulmonary artery pressure; NYHA, New York Heart Association; PAWP, pulmonary
artery wedge pressure; Pra, pravastatin; Sim, simvastatin; Spir, spironolactone; Val, valsartan.
Table 2 Baseline parameters
Parameter
Placebo
(n = 9)
BQ-123
(n = 9)
BQ-123 + BQ-
788 (n = 9)
HR (beats/min) 64 (5) 62 (4) 63 (5)
MAP (mm Hg) 91 (7) 87 (6) 90 (7)
SBP (mm Hg) 106 (8) 104 (9) 106 (9)
DBP (mm Hg) 69 (4) 68 (6) 71 (4)
CVP (mm Hg) 5 (1) 5 (1) 3 (2)
CO (l/min) 5.0 (0.3) 5.5 (0.4) 5.3 (0.3)
SVR (dyn.s/cm25) 1462 (150) 1266 (138) 1344 (138)
MPAP (mm Hg) 16 (1) 16 (1) 17 (2)
PAWP (mm Hg) 11 (2) 11 (1) 12 (3)
PVR (dyn.s/cm25) 83 (12) 91 (14) 78 (18)
Data are mean (SEM).
CO, cardiac output; CVP, central venous pressure; DBP, diastolic blood
pressure; MAP, mean arterial pressure; PVR, pulmonary vascular
resistance; SBP, systolic blood pressure; SVR, systemic vascular
resistance.
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Data and statistical analyses
Data are expressed as mean (SEM) change from baseline or
mean (SEM) area under the curve (AUC) unless otherwise
specified. Data were examined by analysis of variance with
repeated measures over time and Student’s t test with
correction for multiple measures where appropriate (Excel
version 5.0, Microsoft, Redmond, Washington, USA).
Significance was taken at the 5% level.
RESULTS
Table 1 shows baseline patient characteristics and medica-
tions. There were no adverse events and the study was well
tolerated by all patients. There were no significant differences
in baseline haemodynamic variables between study visits
(table 2). Placebo administration caused no significant
changes in haemodynamic variables throughout the course
of the study (analysis of variance p . 0.9).
Cardiac output and heart rate
In comparison with placebo, BQ-123 alone (AUC p , 0.001),
but not BQ-123/788 (AUC p = 0.08), increased cardiac
output with a maximum increase of 33 (12)% at 75 minutes.
Infusion of BQ-123 alone increased cardiac output compared
with BQ-123/788 (AUC p , 0.001) (fig 1C, fig 2). There was
no significant change in heart rate with either BQ-123 alone
(AUC p = 0.38) or BQ-123/788 (AUC p = 0.39) (fig 1A,
fig 2).
Left ventricular fi l l ing pressure and systemic
haemodynamic variables
In comparison with placebo, BQ-123 alone (AUC p = 0.01)
and BQ-123/788 (AUC p , 0.01) reduced pulmonary artery
wedge pressure by a maximum of 19 (7)% at 150 minutes
and 26 (7)% at 105 minutes, respectively (fig 2, fig 3C). There
was no difference between the magnitude of reduction in
pulmonary artery wedge pressure between BQ-123 alone and
BQ-123/788 (AUC p = 0.47). BQ-123 alone (AUC
p , 0.001) and BQ-123/788 (AUC p , 0.05) reduced mean
arterial pressure by a maximum of 14 (5)% and 12 (4)%,
respectively, at 150 minutes. BQ-123 alone reduced mean
arterial pressure to a greater degree than BQ-123/788 (AUC
p , 0.05) (fig 1B, fig 2).
BQ-123 alone (AUC p , 0.001) and BQ-123/788 (AUC
p , 0.05) reduced systemic vascular resistance by a max-
imum of 26 (8)% and 16 (5)%, respectively, at 75 minutes in
comparison with placebo. BQ-123 alone reduced systemic
vascular resistance to a greater degree than BQ-123/788 (AUC
p , 0.05) (fig 1D, figs 2 and 3).
Right ventricular fil l ing pressure and pulmonary
haemodynamic variables
In comparison with placebo, neither BQ-123 alone (AUC
p = 0.17) nor BQ-123/788 (AUC p = 0.69) changed central
venous pressure (fig 2, fig 3A). BQ-123 alone (AUC
p = 0.01) and BQ-123/788 (AUC p = 0.02) reduced mean
pulmonary arterial pressure by a maximum of 25 (7)% and 26
(6)%, respectively, at 90 minutes. There was no significant
difference between these responses (AUC p = 0.98) (fig 2,
fig 3B).
In comparison with placebo, both BQ-123 alone and BQ-
123/788 (AUC both p , 0.001) reduced pulmonary vascular
resistance by a maximum of 72 (39)% and 40 (16)%,
respectively, at 75 minutes. There was no significant
difference between these responses (AUC p = 0.49) (fig 2,
fig 3D).
Plasma ET-1 and big ET-1
There was no change in plasma concentrations of big ET-1
with placebo, BQ-123 alone, or BQ-123/788. There was no
significant change in plasma ET-1 concentrations with
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placebo or BQ-123 alone, whereas BQ-123/788 caused an
increase in plasma ET-1 concentrations (47% with low dose
and 61% with high dose, both p , 0.05) (fig 4).
DISCUSSION
In this randomised placebo controlled crossover study, we
have shown, for the first time, that there are small but
significant haemodynamic differences between the responses
to selective ET-A and non-selective ET-A/B receptor blockade
in patients with chronic heart failure. Both selective ET-A
and non-selective ET-A/B receptor blockade increased cardiac
output and reduced mean arterial pressure and systemic
vascular resistance. However, selective ET-A receptor block-
ade caused a greater increase in cardiac output and reduction
in systemic vascular resistance than non-selective ET-A/B
receptor blockade. In contrast, selective ET-A and non-
selective ET-A/B blockade caused similar reductions in both
pulmonary artery pressure and pulmonary vascular resis-
tance. There was a greater reduction in pulmonary artery
pressure with non-selective blockade than with selective
ET-A blockade after low dose infusion, although this
difference was not apparent after high dose infusion.
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This is the first study to directly compare systemic selective
ET-A and non-selective ET-A/B blockade in patients with
heart failure. Our findings are consistent with other short
term studies, which have shown that both selective ET-A17
and non-selective ET-A/B20–22 blockade increase cardiac out-
put and reduce systemic vascular resistance, importantly
with no change in heart rate, and that both selective ET-A16 17
and non-selective ET-A/B20–22 blockade reduce pulmonary
vascular resistance and pulmonary artery wedge pressure.
Comparing magnitude of response between different ET
antagonists in different patient populations is difficult but we
have shown in this head to head study that selective ET
blockade had greater effects than non-selective ET antagon-
ism on the systemic vasculature.
There is increasing evidence that the ET-B receptor has a
role in the clearance of plasma ET-1. Plasma ET-1 concentra-
tion increases after systemic selective ET-B blockade in
healthy people8 and after non-selective ET-A/B blockade in
healthy people28 and in patients with hypertension4 and with
chronic heart failure.18 20 However, the effects of systemic
ET-A blockade alone are less consistent with little, if any,
increase in plasma ET-1 concentrations in most studies,6 15 16
although one study did report an increase at higher degrees
of ET-A blockade.17 These results are confirmed in our study,
in which selective ET-A receptor blockade had no effect,
whereas plasma ET-1 concentrations were increased by non-
selective blockade. Because there was no change in plasma
big ET-1 concentration, increased plasma ET-1 is likely to
reflect interference with its clearance rather than an increase
in its synthesis and release. Thus, selective ET-A blockade has
a theoretical benefit of leaving the ET clearance receptor
(ET-B) functional. Nevertheless, if the ET-A receptor is also
effectively blocked during ET-B receptor blockade then the
high circulating concentrations of ET-1 may not be of clinical
importance.
Although selective ET-A receptor blockade had greater
effects on systemic vascular resistance, there may be clinical
situations in which blockade of the ET-B receptor is desirable.
There is a higher density of ET-B receptors in the pulmonary
vasculature and these may be upregulated in pulmonary
arterial hypertension,29 though selective ET-A and non-
selective ET-A/B receptor blockade have not yet been
compared head to head in this condition. Also, ET-1 release
across the pulmonary vascular bed correlates strongly with
the pulmonary vascular resistance in chronic heart failure.30
Raised pulmonary artery pressure is an independent risk
factor in chronic heart failure and responds poorly to
conventional treatments. Here, we showed that both selective
ET-A and non-selective ET-A/B receptor blockade reduce
pulmonary artery pressures.
These observations suggest that ET antagonism may
benefit patients with heart failure who also have raised
pulmonary artery pressures, although we did not directly
address this condition in our study. Indeed, the non-selective
antagonist bosentan has recently been approved to treat
primary pulmonary arterial hypertension based on its
effectiveness in this situation.31 The long term clinical effects
of ET receptor blockade in patients with pulmonary
hypertension secondary to chronic heart failure are
unknown, but it is tempting to speculate that ET receptor
blockade may also be more effective in this setting. We have
failed to show convincingly whether there are true haemo-
dynamic differences between selective ET-A and non-
selective ET-A/B receptor antagonism in the pulmonary
circulation. However, none of the patients in the present
study had significant pulmonary hypertension. We believe
that the role of ET antagonism now warrants further careful
assessment in a much larger trial of patients with both heart
failure and a significant degree of pulmonary hypertension.
Many studies use agents that, while termed ‘‘selective’’ or
‘‘dual’’ inhibitors of ET-A and ET-B receptors, have a range of
receptor selectivities, mostly inhibiting the ET-A receptor at
much lower concentrations than at the ET-B receptor.26 In
this study we have used two receptor antagonists, BQ-123
and BQ-788, given separately and with selectivity for the ET-
A and ET-B receptor, respectively. Therefore, it is important
to recognise that we have examined mechanistically the
influence of major blockade of the ET-B receptor on
responses to full ET-A blockade. This may not exactly
represent the clinical situation that exists with non-selective
antagonists, such as bosentan, which are relatively selective
for the ET-A receptor (ET-A:ET-B selectivity . 10). The doses
of BQ-123 given here have been shown to produce maximum
systemic haemodynamic effects and to block responses to
forearm artery infusion of ET-1, but not to increase plasma
ET-1 concentrations. Given that BQ-123 caused greater
systemic vasodilatation than the combination with BQ-788,
the overall haemodynamic effect of ET-B blockade in patients
with heart failure is likely to be vasoconstriction, a finding
consistent with other work.23 32
As a limitation, this was an acute haemodynamic study
and we have not assessed whether these effects are sustained
in the long term. Nevertheless, previous haemodynamic
studies indicate that the acute effects of both selective ET-A24
and non-selective32 ET receptor blockade are maintained, or
even enhanced, over several weeks and therefore likely to be
sustained. The clinical impact of these haemodynamic
changes is, of course, uncertain and can only be clarified in
the context of large scale clinical outcome studies. We have
shown that selective ET-A blockade causes more major
systemic vasodilatation than non-selective ET-A/B receptor
blockade in New York Heart Association (NYHA) class II–III
patients with heart failure. To date, there have been only
two as yet unpublished large scale, randomised controlled
trials of ET receptor blockade in patients with heart failure
(NYHA class III–IV), both of which observed no major
clinical benefit of either bosentan (ET-A:ET-B selectivity
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,10)25 or darusentan (ET-A:ET-B selectivity . 500).24 The
results of these longer term studies were disappointing,
although perhaps it is not surprising that two agents with 10
to . 500 selectivity for the ET-A receptor yielded similar
results given the small haemodynamic differences found in
the current study, when much greater relative ET-B receptor
blockade was achieved. Nevertheless, bosentan has found
utility in the treatment of primary pulmonary hypertension
and whether it may have utility in a subset of patients with
CHF with secondary pulmonary hypertension remains to be
seen.
Conclusions
In this study both selective ET-A and non-selective ET-A/B
blockade cause acute systemic and pulmonary haemody-
namic changes in patients with heart failure. However,
differences exist and selective ET-A blockade causes greater
systemic haemodynamic effects than non-selective ET-A/B
blockade.
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